Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients

Mirati Therapeutics Inc MRTX has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined with Bristol-Myers Squibb Co's BMY Opdivo (nivolumab).
The trial included 68 patients with second or third-line non-squamous non-small cell lung cancer (NSCLC) who experienced clinical benefit on a prior checkpoint inhibitor (CPI) and subsequent disease progression.
The data were presented at the European Society for Medical Oncology Congress (ESMO21) 2021.
The combination therapy posted a median progression-free survival (PFS) was 5.7 months.
The median overall survival was 14.9 months, with 56% and 32% of these patients alive at one year and two years, respectively.
The objective response rate was 18%, with 3% of patients achieving a complete response and 15% of patients achieving a partial response.
The median duration of response was 12.8 months.
The sitravatinib and nivolumab combination was well-tolerated and consistent with what was previously reported.
Grade 3/4 treatment-related adverse events (TRAEs) were reported in 66% of patients. The rate of TRAEs leading to discontinuation was 22%
Mirati says that the results support its ongoing Phase 3 SAPPHIRE study evaluating the combo therapy in NSCLC patients who are resistant to immune checkpoint inhibitor therapy.
Interim overall survival readout is expected in 2H of 2022.
Price Action: MRTX stock is up 2.28% at $178.01 during the market session on the last check Monday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga